Association between the TP53 codon72 polymorphism and oral cancer risk and prognosis

Oral Oncology

Volumn 43, Issue 10, 2007, Pages 1043-1048

  Kuroda, Yoshiki ^a   Nakao, Hiroyuki ^a   Ikemura, Kunio ^b   Katoh, Takahiko ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Genotype; Head and neck; Smoking

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SURVIVAL; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CODON; FEMALE; GENES, P53; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; ODDS RATIO; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS;

EID: 34948828484     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2006.12.001     Document Type: Article

References (44)

1. Doll R., and Peto R. The causes of cancer (1981), Oxford University Press, New York
2. Lazarus P., Sheikh S.N., Ren Q., Schantz S.P., Stern J.C., Richie Jr. J.P., et al. p53, but not p16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1 and GSTM1 polymorphic genotypes and patient tobacco use. Carcinogenesis 19 3 (1998) 509-514
3. McKaig R.G., Baric R.S., and Olshan A.F. Human papillomavirus and head and neck cancer: epidemiology and molecular biology. Head Neck 20 3 (1998) 250-265
4. Fouret P., Monceaux G., Temam S., Lacourreye L., and St Guily J.L. Human papillomavirus in head and neck squamous cell carcinomas in nonsmokers. Arch Otolaryngol Head Neck Surg 123 5 (1997) 513-516
5. Kabat G.C., Chang C.J., and Wynder E.L. The role of tobacco, alcohol use, and body mass index in oral and pharyngeal cancer. Int J Epidemiol 23 6 (1994) 1137-1144
6. Blot W.J., McLaughlin J.K., Winn D.M., Austin D.F., Greenberg R.S., Preston-Martin S., et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 48 11 (1988) 3282-3287
7. De Andrade M., Amos C.I., and Foulkes W.D. Segregation analysis of squamous cell carcinoma of the head and neck: evidence for a major gene determining risk. Ann Hum Genet 62 6 (1998) 505-510
8. Vineis P. Epidemiology of cancer from exposure to arylamines. Environ Health Perspect 102 Suppl 6 (1994) 7-10
9. Felton J.S., Knize M.G., Dolbeare F.A., and Wu R. Mutagenic activity of heterocyclic amines in cooked foods. Environ Health Perspect 102 Suppl 6 (1994) 201-204
10. Fu P.P., Herreno-Saenz D., Von Tungeln L.S., Lay J.O., Wu Y.S., Lai J.S., et al. DNA adducts and carcinogenicity of nitro-polycyclic aromatic hydrocarbons. Environ Health Perspect 102 Suppl 6 (1994) 177-183
11. Roy B., Beamon J., Balint E., and Reisman D. Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol 14 12 (1994) 7805-7815
12. Vogelstein B., and Kinzler K.W. p53 function and dysfunction. Cell 70 4 (1992) 523-526
13. Jensen R.A., and Page D.L. p53: the promising story continues to unfold. Human Pathol 24 5 (1993) 455-456
14. Harris C.C. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 262 5142 (1993) 1980-1981
15. Weston A., Perrin L.S., Forrester K., Hoover R.N., Trump B.F., Harris C.C., et al. Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev 1 6 (1992) 481-483
16. Kawajiri K., Nakachi K., Imai K., Watanabe J., and Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14 6 (1993) 1085-1089
17. Jin X., Wu X., Roth J.A., Amos C.I., King T.M., Branch C., et al. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 16 9 (1995) 2205-2208
18. Murata M., Tagawa M., Kimura H., Kakisawa K., Shirasawa H., and Fujisawa T. Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients. Int J Oncol 12 3 (1998) 577-581
19. Kuroda Y., Tsukino H., Nakao H., Imai H., and Katoh T. p53 Codon 72 polymorphism and urothelial cancer risk. Cancer Lett 189 1 (2003) 77-83
20. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., and Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19 2 (1999) 1092-1100
21. Tandle A.T., Sanghvi V., and Saranath D. Determination of p53 genotypes in oral cancer patients from India. Br J Cancer 84 6 (2001) 739-742
22. Summersgill K.F., Smith E.M., Kirchner H.L., Haugen T.H., and Turek L.P. p53 polymorphism, human papillomavirus infection in the oral cavity, and oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90 3 (2000) 334-339
23. Kietthubthew S., Sriplung H., Au W.W., and Ishida T. The p53 codon 72 polymorphism and risk of oral cancer in Southern Thailand. Asian Pac J Cancer Prev 4 3 (2003) 209-214
24. Ara S., Lee P.S., Hansen M.F., and Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 18 16 (1990) 4961
25. Wang Y.C., Chen C.Y., Chen S.K., Chang Y.Y., and Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 5 1 (1999) 129-134
26. Twu C.W., Jiang R.S., Shu C.H., and Lin J.C. Association of p53 codon 72 polymorphism with risk of hypopharyngeal squamous cell carcinoma in Taiwan. J Formos Med Assoc 105 2 (2006) 99-104
27. Tsai M.H., Lin C.D., Hsieh Y.Y., Chang F.C., Tsai F.J., Chen W.C., et al. Prognostic significance of the proline form of p53 codon 72 polymorphism in nasopharyngeal carcinoma. Laryngoscope 112 1 (2002) 116-119
28. Pierce L.M., Sivaraman L., Chang W., Lum A., Donlon T., Seifried A., et al. Relationships of TP53 codon 72 and HRAS1 polymorphisms with lung cancer risk in an ethnically diverse population. Cancer Epidemiol Biomarkers Prev 9 11 (2000) 1199-1204
29. Murata M., Tagawa M., Kimura M., Kimura H., Watanabe S., and Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis 17 2 (1996) 261-264
30. Ueda M., Terai Y., Kanda K., Kanemura M., Takehara M., Yamaguchi H., et al. Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol 100 1 (2006) 173-178
31. Sakamuro D., Sabbatini P., White E., and Prendergast G.C. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15 8 (1997) 887-898
32. Walker K.K., and Levine A.J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA 93 26 (1996) 15335-15340
33. Dumont P., Leu J.I., Della Pietra III A.C., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33 3 (2003) 357-365
34. Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393 6682 (1998) 229-234
35. Schwartz S.M., Daling J.R., Doody D.R., Wipf G.C., Carter J.J., Madeleine M.M., et al. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 90 21 (1998) 1626-1636
36. Maden C., Beckmann A.M., Thomas D.B., McKnight B., Sherman K.J., Ashley R.L., et al. Human papillomaviruses, herpes simplex viruses, and the risk of oral cancer in men. Am J Epidemiol 135 10 (1992) 1093-1102
37. Cortezzi S.S., Provazzi P.J., Sobrinho J.S., Mann-Prado J.C., Reis P.M., de Freitas S.E., et al. Analysis of human papillomavirus prevalence and TP53 polymorphism in head and neck squamous cell carcinomas. Cancer Genet Cytogenet 150 1 (2004) 44-49
38. Woods K.V., Shillitoe E.J., Spitz M.R., Schantz S.P., and Adler-Storthz K. Analysis of human papillomavirus DNA in oral squamous cell carcinomas. J Oral Pathol Med 22 3 (1993) 101-108
39. Brandwein M., Zeitlin J., Nuovo G.J., MacConnell P., Bodian C., Urken M., et al. HPV detection using hot start polymerase chain reaction in patients with oral cancer: a clinicopathological study of 64 patients. Mod Pathol 7 7 (1994) 720-727
40. Tachezy R., Klozar J., Salakova M., Smith E., Turek L., Betka J., et al. HPV and other risk factors of oral cavity/oropharyngeal cancer in the Czech Republic. Oral Dis 11 3 (2005) 181-185
41. Amos C.I., Caporaso N.E., and Weston A. Host factors in lung cancer risk: a review of interdisciplinary studies. Cancer Epidemiol Biomarkers Prev 1 6 (1992) 505-513
42. Khoury M.J., Adams Jr. M.J., and Flanders W.D. An epidemiologic approach to ecogenetics. Am J Hum Genet 42 1 (1988) 89-95
43. Katiyar S., Thelma B.K., Murthy N.S., Hedau S., Jain N., Gopalkrishna V., et al. Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem 252 1-2 (2003) 117-124
44. Buller R.E., Sood A., Fullenkamp C., Sorosky J., Powills K., and Anderson B. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther 4 4 (1997) 239-245